Partners in Care
As innovators, we are proud to join forces with world-class partners who can help us develop and commercialize therapies to advance treatments for patients living with life-threatening diseases.
National Cancer Institute (NCI)
In 2011, we entered into a five-year Cooperative Research and Development Agreement (CRADA) with the NCI's Division of Cancer Treatment and Diagnosis to collaborate on the development of IMBRUVICA® (ibrutinib) in various hematologic malignancies through multiple sponsored trials and several investigator-sponsored trials.
In 2011, we entered a collaboration with Janssen Biotech, Inc., (one of the Janssen Pharmaceutical Companies of Johnson & Johnson) to develop and commercialize IMBRUVICA® (ibrutinib) for oncology and other indications, excluding inflammation and immune-mediated conditions.
Novo Nordisk A/S has licensed the rights to our Factor Vlla inhibitor PCI-27483 in a restricted indication outside of oncology. The company will use the small molecule as an excipient (an inactive substance) formulated with active ingredients to enable the development of a new product formulation.
In 2013, Onyx Pharmaceuticals, Inc., an Amgen subsidiary, partnered with us to evaluate the potential of IMBRUVICA® (ibrutinib) with KYPROLIS® (carfilzomib) for Injection, as a potential combination therapy for patients with mantle cell lymphoma (MCL) and multiple myeloma (MM).
KYPROLIS is a registered trademark of Onyx Pharmaceuticals, Inc.
In 2014, AstraZeneca partnered with us and entered into three different collaboration agreements to evaluate IMBRUVICA® (ibrutinib) in combination with their investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 and P13 kinase pathway inhibitors. In one collaboration, we partnered together with AstraZeneca, Janssen Research & Development LLC to evaluate IMBRUVICA® in combination with MEDI4735 as a potential treatment for patients with hematologic cancers including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In another agreement, AstraZeneca partnered with us to evaluate the combination of IMBRUVICA® and MEDI4736 as a novel combination therapy targeting solid tumors. In the third agreement, we partnered to explore separately two different investigational P13 kinase pathway inhibitors in combination with IMBRUVICA® for treating relapsed or refractory DLBCL patients.
In 2014, Bristol-Myers Squibb partnered with us and Janssen Research & Development LLC to collaboratively evaluate its investigational PD-1 immune checkpoint inhibitor nivolumab in combination with IMBRUVICA® as a potential treatment option for patients with non-Hodgkin lymphoma (NHL), including relapsed DLBCL, relapsed FL, and relapsed chronic lymphocytic leukemia (CLL).
In 2013 and 2014, we entered into two agreements with Celgene to explore potential combination therapies in relapsed or refractory DLBCL. The first evaluates the combination of IMBRUVICA® (ibrutinib) with REVLIMID® (lenalidomide) and RITUXAN® (rituximab), and the second evaluates IMBRUVICA® and REVLIMID® together with DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen plus rituximab).
REVLIMID is a registered trademark of Celgene Corporation.
RITUXAN is a registered trademark of Biogen Idec, Inc.
In 2014, we entered into an agreement with Roche to evaluate IMBRUVICA® in combination with GAZYVA® (obinutuzumab), a new CD20-directed antibody that attacks targeted cells, both directly and together with the body's immune system, in patients with CLL/SLL.
GAZYVA is a registered trademark of Genentech, Inc.